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Evolocumab in Patients with Cardiovascular Disease
To the Editor: Sabatine et al. (May 4 issue)1 re-
port the results of the Further Cardiovascular 
Outcomes Research with PCSK9 Inhibition in 
Subjects with Elevated Risk (FOURIER) trial. The 
addition of evolocumab to standard therapy was 
associated with an absolute risk reduction of 2 
percentage points in both the primary and sec-
ondary end points after a median duration of 
follow-up of 26 months.
The fact that approximately 30% of the pa-
tients were receiving moderate-intensity statin 
therapy and the lack of clinical efficacy of evo-
locumab in the small group of patients receiving 
ezetimibe (presumably combined with a statin) 
arouse concern about the desirability of achiev-
ing such a marginal absolute risk reduction by 
inhibiting proprotein convertase subtilisin–kexin 
type 9 (PCSK9) in patients receiving high-inten-
sity statin therapy, combined with ezetimibe, as 
appropriate. The results of trials that show a 
cardiovascular benefit of the addition of ezeti-
mibe to statins2,3 support the role of this combi-
nation as an initial lipid-lowering strategy in 
patients at high cardiovascular risk.
Given the findings of the FOURIER trial, in 
patients at high cardiovascular risk in whom 
low-density lipoprotein (LDL) cholesterol goals 
cannot be achieved despite the use of lipid-low-
ering treatment, it would be more cost-effective 
to add evolocumab to a high-intensity statin com-
bined with ezetimibe, as needed and if this 
combination has an acceptable side-effect pro-
file. These recommendations are consistent with 
current guidelines that were published after 
PCSK9 inhibitors became available.4,5
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To the Editor: In the FOURIER trial, Sabatine 
et al. found a reduction in the risk of cardiovas-
cular events among patients with preexisting 
atherosclerotic disease who received evolocumab 
on a background of statin therapy. The data show 
geographic heterogeneity with respect to clini-
cally serious secondary end points. As shown in 
Figure S5 in the Supplementary Appendix (avail-
able with the full text of the article at NEJM.org), 
a total of 17,335 patients from Europe (63% of 
the enrolled population) derived a lesser benefit 
from evolocumab on the key secondary compos-
ite end point of cardiovascular death, myocardial 
infarction, or stroke (hazard ratio, 0.90; 95% 
confidence interval [CI], 0.80 to 1.01) than pa-
tients from North America (hazard ratio, 0.62; 
95% CI, 0.51 to 0.76) (P = 0.01 for the interaction).
The inconsistency of the benefit across major 
regions may have considerable cost-effectiveness 
implications. We estimate that the number of pa-
tients who would need to be treated for 3 years 
to prevent one cardiovascular death, myocardial 
infarction, or stroke is almost 4 times as high in 
Europe as in North America. Under the assump-
tion that the annual list price of evolocumab is 
$14,350,1 preventing one such event would cost 
approximately $861,000 in North America and 
$3,314,850 in Europe. We wonder whether these 
variations were driven by baseline risk differ-
ences, a discrepancy between Europe and North 
America in rates of diagnosis of cardiovascular 
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events (event rates in the placebo group, 6.7% vs. 
10.6%), or differences in adherence to treatment.
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To the Editor: The FOURIER trial showed that 
evolocumab significantly reduced the risk of car-
diovascular events among patients with athero-
sclerotic cardiovascular disease who were receiv-
ing statin therapy. The percentage of patients with 
diabetes in this trial (36.6%) was higher than in 
most secondary-prevention trials of statins.1 It 
would be interesting to know the effect of evo-
locumab in relation to the diabetic status of the 
patients. Notably, in patients with or without dia-
betes, statins result in a similar reduction in car-
diovascular risk1 and similar favorable effects on 
coronary atherosclerosis2 for a given magnitude 
of LDL cholesterol lowering. In contrast, the clin-
ical benefit of the nonstatin agent ezetimibe is 
most pronounced in patients who have diabetes.3
The important insights provided by the 
FOURIER trial substantiate the concept that low-
ering the LDL cholesterol level below current 
targets is associated with a better clinical prog-
nosis, but they also point to the need to identify 
patients who are likely to derive the greatest 
clinical benefit from this generally effective (yet 
expensive) intervention. Assessment of the clini-
cal effects of evolocumab in patients with diabe-
tes, who frequently have treatment-resistant dys-
lipidemia, complex atherosclerotic disease, and 
recurrent cardiovascular events,4 may enhance 
clinical decision making regarding the lowering of 
LDL cholesterol levels in very high-risk patients.
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To the Editor: The FOURIER trial showed no 
benefit of evolocumab on cardiovascular mortal-
ity after 26 months, and there was a nonsignifi-
cant increase in deaths from any cause among 
patients who received evolocumab as compared 
with those who received placebo (444 deaths vs. 
426 deaths). However, there was a 1.2-percentage-
point absolute difference in the rate of myocar-
dial infarction in the evolocumab group. One 
explanation is that most of the myocardial in-
farctions in the trial were not ST-segment eleva-
tion myocardial infarctions (STEMIs) but were 
related to elevated troponin levels of unclear 
clinical significance. These myocardial infarc-
tions of lesser severity could be related to the fact 
that more patients underwent revascularization 
(which is associated with elevated troponin levels) 
in the placebo group than in the evolocumab 
group. Could the authors provide rates of STEMI, 
non-STEMI with a risk of a Thrombolysis in Myo-
cardial Infarction (TIMI) risk score greater than 2, 
and non-STEMI with a TIMI risk score of 2 or less?
Furthermore, the high price of PCSK9 therapy 
— $14,000 per year1 — and the large number 
needed to treat must be considered. The cost to 
avert one myocardial infarction is $2.4 million, 
and the cost to avert one stroke is $7.5 million. 
The proposal by Amgen1 to issue a rebate if a 
myocardial infarction or stroke occurs is no real 
discount; since modern event rates are low, this 
amounts to a 5% reduction in price. Unreason-
ably high drug prices in the United States and 
globally are a major concern.
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To the Editor: The article by Sabatine et al. on the 
effects of evolocumab in patients with cardiovas-
cular disease clearly shows that evolocumab, 
added to statin therapy, decreases both LDL cho-
lesterol levels and the risk of cardiovascular 
events, including myocardial infarction and stroke. 
However, more intensive lowering of LDL choles-
terol levels, as compared with less intensive ther-
apy with statins, does not lead to a decrease in 
overall mortality.
This mortality paradox appears to be a repro-
ducible phenomenon. High-intensity statin ther-
apy in the Treating to New Targets (TNT) trial, 
the Incremental Decrease in Endpoints Through 
Aggressive Lipid Lowering (IDEAL) trial, and the 
Study of the Effectiveness of Additional Reductions 
in Cholesterol and Homocysteine (SEARCH), the 
combination of ezetimibe and statin therapy in 
the Improved Reduction of Outcomes: Vytorin 
Efficacy International Trial (IMPROVE-IT), and 
now the combination of evolocumab with a statin 
in the FOURIER trial all fail to reduce overall 
mortality, as compared with less intensive LDL 
cholesterol–lowering therapy that includes statins. 
These findings suggest that a common biologic 
phenomenon could be at play.1
A total of 1440 patients were treated con-
comitantly with ezetimibe. It would be interest-
ing to look at the data on hospitalization for 
unstable angina and coronary revascularization, 
given the differential effect of evolocumab on 
the primary and key secondary outcome in this 
group of patients.
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The authors reply: García de Tena et al. com-
ment on absolute risk reductions but neglect to 
account for treatment duration. The 2-percentage-
point absolute reduction in the rate of cardiovas-
cular death, myocardial infarction, or stroke with 
evolocumab occurred over a period of 2.2 years. 
In comparison, it took nearly 5 years to see a 
2.2-percentage-point reduction in major vascular 
events with high-intensity statin therapy versus 
moderate-intensity statin therapy.1 The number 
needed to treat to prevent one major vascular 
event over 5 years would be 45 with high-intensity 
statin therapy and only 30 with evolocumab. 
Their statement that there was no efficacy in pa-
tients receiving ezetimibe is incorrect; there was 
no heterogeneity in the benefit of evolocumab 
according to ezetimibe use.
Naci and Mehra note significant heterogene-
ity in the hazard ratio for the key secondary end 
point according to geographic region, but with-
out correction for multiple hypothesis testing. 
Moreover, there was no heterogeneity for the 
primary end point. There were no clinically im-
portant differences in base line characteristics, 
adherence to treatment tended to be better in 
Europe, and, unsurprisingly, among the individual 
outcomes, revascularization rates differed most 
according to region.
Koskinas and Windecker inquire about the 
efficacy of evolocumab in patients with diabetes. 
These data have not been analyzed.
Redberg and Prasad speculate that the reduc-
tion in the risk of myocardial infarction could 
have been driven by elevated troponin levels of 
unclear clinical significance in patients who 
underwent revascularization. The data in the 
FOURIER trial parallel those from similar co-
horts described in the literature that clearly show 
that such a supposition is unfounded, since type 
4a myocardial infarctions (related to revascular-
ization) accounted for only approximately 1% of 
all myocardial infarctions, and the majority of 
patients with spontaneous myocardial infarctions 
had troponin levels that were 10 or more times 
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the upper limit of the normal range.2,3 As noted 
above, the number needed to treat with evolocu-
mab compares favorably to that with high-inten-
sity statins, once the duration of treatment is 
taken into account.
Nunes comments on the lack of a benefit with 
respect to mortality in recent trials involving 
patients who were already receiving moderate-
intensity statin therapy. Rather than a paradox, 
we think this observation reflects, first, the lower 
case fatality rate associated with myocardial 
infarction and stroke than that in early trials 
(e.g., the Scandinavian Simvastatin Survival Study 
[4S]) that showed a mortality benefit and, sec-
ond, the need for prolonged follow-up to see 
whether reductions in the risk of nonfatal myo-
cardial infarction and stroke translate into 
 reduced cardiovascular mortality. Genetic var-
iants in PCSK9 that lower LDL cholesterol lev-
els on a lifelong basis confer the same reduc-
tion in coronary mortality as do analogous 
variants in HMGCR4; these findings support our 
contention.
Marc S. Sabatine, M.D., M.P.H. 
Robert P. Giugliano, M.D.
Brigham and Women’s Hospital 
Boston, MA 
msabatine@ partners . org
Terje R. Pedersen, M.D.
Oslo University Hospital 
Oslo, Norway
Since publication of their article, Dr. Sabatine reports receiv-
ing honoraria from Janssen Research and Development. No 
further potential conflict of interest relevant to this letter was 
reported.
1. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid low-
ering with atorvastatin in patients with stable coronary disease. 
N Engl J Med 2005; 352: 1425-35.
2. Kidd SK, Bonaca MP, Braunwald E, et al. Universal classifi-
cation system type of incident myocardial infarction in patients 
with stable atherosclerosis: observations from Thrombin Recep-
tor Antagonist in Secondary Prevention of Atherothrombotic 
Ischemic Events (TRA 2°P)-TIMI 50. J Am Heart Assoc 2016; 5(7): 
e003237.
3. Bonaca MP, Wiviott SD, Morrow DA, et al. Reduction in 
subtypes and sizes of myocardial infarction with ticagrelor in 
PEGASUS-TIMI 54. Circulation 2015; 132: Suppl 3: A11594. abstract.
4. Ference BA, Robinson JG, Brook RD, et al. Variation in PCSK9 
and HMGCR and risk of cardiovascular disease and diabetes. 
N Engl J Med 2016; 375: 2144-53.
DOI: 10.1056/NEJMc1708587
Trial of Minocycline in Clinically Isolated Syndrome  
of Multiple Sclerosis
To the Editor: The conclusion of Metz et al. 
(June 1 issue)1 — that the risk of conversion from 
a clinically isolated syndrome to multiple sclero-
sis was significantly lower with minocycline than 
with placebo at 6 months — may not be entirely 
well founded. The baseline imbalance between 
the two randomly assigned groups may have penal-
ized the placebo group by including a larger pro-
portion of patients with spinal cord and multi-
focal symptoms at onset, a larger proportion of 
patients with two or more enhancing lesions on 
magnetic resonance imaging, and a larger num-
ber of patients fulfilling the 2010 McDonald cri-
teria2 of multiple sclerosis. The results are incon-
sistent with other studies such as the RECYCLINE 
trial.3 A recent Cochrane review4 showed that 
early treatment with nearly all disease-modifying 
drugs reduced the probability of short-term con-
version to multiple sclerosis, although the clini-
cal benefit with respect to long-term relapse and 
disability worsening remains uncertain.
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